13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SCHEDULE 13D Filed 2026-10-21 Event 2026-10-15 SEC 0001193125-26-428005 →

Frazier Life Sciences Holdings II LLC → Frazier Life Sciences Acquisition Corp. II FLSC

Stake: 20.50% Shares: 1,983,749 CUSIP: G37103101 Class: Class A ordinary shares, $0.0001 par value

Item 4 — Purpose of Transaction

The information set forth in Items 3 and 6 hereof is incorporated by reference in its entirety into this Item 4. The securities described herein were acquired solely for investment purposes. The Reporting Persons reserve the right to acquire, or dispose of, additional securities of the Issuer in the ordinary course of their business, to the extent deemed advisable in light of their general investment and trading policies, market conditions or other factors. The Reporting Persons may engage in discussions from time to time with other stockholders of the Issuer regarding the acquisition by the Reporting Persons or others of shares of the Issuer's Ordinary Shares held by such stockholders. Additionally, the Reporting Persons may acquire additional securities through open market transactions, privately negotiated transactions or other methods. In connection with the foregoing, and as may be appropriate from time to time, each of the Reporting Persons may consider the feasibility and advisability of various alternative courses of action with respect to the Reporting Persons' investment in the Issuer, including, without limitation: (a) the acquisition or disposition of Ordinary Shares, including through derivative transactions which may include security-based swaps and short sales; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) changes in the present board of directors or management of the Issuer; (e) a material change in the present capitalization or dividend policy of the Issuer; (f) other material changes in the Issuer's business or corporate structure; (g) changes in the Issuer's articles of incorporation or bylaws or other actions that may impede the acquisition of control of the Issuer by any person; (h) causing any class of the Issuer's securities to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) causing a class of equity securities of the Issuer to become eligible for termination of registration pursuant to Section 12 of the Exchange Act; or (j) any action similar to those enumerated above. Except as described in this Item 4, the Reporting Persons do not currently have any plans or proposals that relate to or would result in any of the actions specified in clause (a) through (j) of this paragraph. The Reporting Persons intend to review their investment in the Issuer from time to time on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's stock in particular, as well as other developments.

Cross-References

Insider Activity (last 365d)
0 transactions
0 buys · 0 sales · 0 awards/exercises
Issuer Cluster
4 13D/G filings on this issuer
3 other filings besides this one
Filer Track Record
1 filings by this filer
0 other filings in the data moat
Short Interest
—
Not in latest FINRA snapshot

Other 13D/G Filings on Frazier Life Sciences Acquisition Corp. II

FiledFormFilerStakeShares
2026-10-21 SCHEDULE 13G BIOTECHNOLOGY VALUE FUND L P — — view →
2026-10-21 SCHEDULE 13G Deep Track Capital, LP — — view →
2026-10-16 SCHEDULE 13G Coastlands Capital LP — — view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →